Hypothesis

Aging‑associated gut barrier dysfunction is not uniform along the colon; it is amplified in the descending colon due to higher luminal concentrations of secondary bile acids that activate FXR, leading to repression of CB₁ receptor expression in enteric neurons and subsequent up‑regulation of miR‑191‑5p. This miRNA‑mediated post‑transcriptional silencing of ZO‑1 and occludin outweighs the modest, region‑specific increase in occludin transcription observed in older adults, producing a net loss of barrier protein where the bile acid gradient is steepest.

Mechanistic Rationale

1. Bile acid gradient: Conventional and recent metabolomic studies show a proximal‑to‑distal increase in deoxycholic acid (DCA) and lithocholic acid (LCA) in the aged colon, mirroring the higher occludin mRNA reported in the descending colon [1].
2. FXR‑CB₁ cross‑talk: Activation of FXR by DCA/LCA suppresses CB₁ transcription in neuronal and epithelial cells via a SHP‑dependent mechanism (inferred from hepatic FXR‑CB₁ antagonism studies) [5]. Reduced CB₁ signaling removes its tonic inhibition of NF‑κB p65, permitting NF‑κB‑driven transcription of miR‑191‑5p [5].
3. miR‑191‑5p dominance: While miR‑29a also rises with age [4], its target affinity for ZO‑1 is lower than that of miR‑191‑5p, and miR‑191‑5p simultaneously targets occludin and JAM‑A, creating a broader destabilizing effect [4,5].
4. Regional vulnerability: The descending colon experiences the highest bile acid load, thus the strongest FXR‑mediated CB₁ repression and miR‑191‑5p induction, explaining why occludin mRNA is elevated (compensatory transcriptional response) yet protein is depleted [1].

Testable Predictions

• Prediction 1: In aged mice, pharmacological inhibition of FXR (e.g., with glyursodeoxycholic acid) or neutralization of luminal DCA/LCA will restore CB₁ expression in the myenteric plexus and decrease miR‑191‑5p levels specifically in the descending colon.
• Prediction 2: Local colonic delivery of an antagomir against miR‑191‑5p will rescue ZO‑1 and occludin protein abundance and reduce serum zonulin, without altering CB₁ expression.
• Prediction 3: Conversely, overexpression of miR‑191‑5p in young mice will recapitulate the descending‑colon‑specific barrier defect, even when CB₁ signaling is intact.

Experimental Design

1. Animal cohorts: Young (3 mo) and aged (24 mo) C57BL/6 mice; groups receive (a) vehicle, (b) FXR antagonist, (c) bile acid sequestrant (cholestyramine) via drinking water, (d) colonic enema of miR‑191‑5p antagomir, (e) control antagomir.
2. Readouts: qPCR for CB₁, miR‑191‑5p, miR‑29a; Western blot/ZO‑1 immunofluorescence for ZO‑1, occludin, JAM‑A in ascending vs descending colon sections; serum zonulin and LPS‑binding protein; colonic permeability to FITC‑dextran.
3. Controls: Verify that FXR antagonism does not alter miR‑29a levels to isolate the miR‑191‑5p pathway.

Potential Outcomes and Falsifiability

• If FXR blockade or bile acid sequestration normalizes CB₁ and reduces miR‑191‑5p only in the descending colon, and this coincides with restored tight‑junction protein levels and lowered zonulin, the hypothesis is supported.
• If miR‑191‑5p antagomir rescues barrier function despite unchanged CB₁, it confirms miR‑191‑5p as the dominant effector downstream of bile acid/FXR signaling.
• Failure to observe any regional differences, or a lack of effect of FXR/bile acid manipulation on miR‑191‑5p and barrier markers, would falsify the proposed mechanism and suggest that other regional factors (e.g., epithelial oxygen tension, microbiota composition) dominate.

By linking microbiota‑derived bile acid signaling to the CB₁‑miR‑191‑5p axis, this hypothesis explains the observed transcriptional‑protein disconnect, provides a spatially resolved mechanism for aging‑related barrier leak, and offers druggable targets (FXR, bile acid sequestration, miR‑191‑5p antagomirs) that can be directly tested in vivo.